title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Wednesday,20220511T162815,https://www.benzinga.com/markets/options/22/05/27141482/52-weeks-high-and-low-article,GMAB,0.006905,Neutral,0.006537
"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More",20220414T133544,https://www.benzinga.com/general/biotech/22/04/26630399/the-daily-biotech-pulse-pfizer-biontech-covid-19-booster-data-in-kids-regenerons-covid-19-therapy,GMAB,0.08395,Neutral,0.011626
ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products - Lonza Group  ( OTC:LZAGY ) ,20230913T070000,https://www.benzinga.com/pressreleases/23/09/n34521672/abl-bio-taps-into-synaffix-adc-technology-to-accelerate-development-of-bispecific-adc-products,GMAB,0.040484,Neutral,0.084387
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,20230626T210100,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,GMAB,0.020903,Neutral,0.064977
Synaffix Announces Expansion of ADC Collaboration with MacroGenics,20230314T121400,https://www.prnewswire.com/news-releases/synaffix-announces-expansion-of-adc-collaboration-with-macrogenics-301771459.html,GMAB,0.054732,Neutral,0.101808
"Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline",20230206T080000,https://www.prnewswire.com/news-releases/chong-kun-dang-pharm-licenses-synaffix-adc-technology-adds-novel-adc-candidate-to-oncology-pipeline-301738575.html,GMAB,0.049526,Neutral,0.111163
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs,20230105T140000,https://www.prnewswire.com/news-releases/synaffix-enters-license-agreement-with-amgen-to-build-next-generation-adcs-301714411.html,GMAB,0.059636,Somewhat-Bullish,0.190027
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate  ( ADC )  Program,20230104T191500,https://www.benzinga.com/pressreleases/23/01/n30280537/hummingbird-bioscience-and-synaffix-enter-license-agreement-to-develop-a-next-generation-antibody-,GMAB,0.044469,Neutral,0.110091
Another Award for Synaffix: 'Business Development Team of Year' at the Scrip Awards,20221213T080000,https://www.prnewswire.com/news-releases/another-award-for-synaffix--business-development-team-of-year-at-the-scrip-awards-301700641.html,GMAB,0.102888,Somewhat-Bullish,0.180641
